Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein and Special Advisor Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has signed their first contract for their slow release tablets with MediPharm.
Goldstein discusses how the deal with work and what is it worth to the company. Meanwhile, Latowsky discusses why he is joining the company and what he sees as the big advantages Canntab has over others.
Price: 0.83 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CEO Larry Latowski and CFO Richard Goldstein joined Steve Darling from Proactive with news the company has completed its first delivery of two of five SKU's ordered by MediPharm Labs. Goldstein and Latowski tall about them taking this major step...
Health
Industry & services
Retail & consumer
Finance
Mining
Prev article
